Selective Inhibition of Bicyclic Tetrapeptide Histone Deacetylase Inhibitor on HDAC4 and K562 Leukemia Cell |
Li, Xiao-Hui
(School of Life Science and Biotechnology, Dalian University of Technology)
Huang, Mei-Ling (School of Life Science and Biotechnology, Dalian University of Technology) Wang, Shi-Miao (School of Life Science and Biotechnology, Dalian University of Technology) Wang, Qing (School of Pharmaceutical Science and Technology, Dalian University of Technology) |
1 | Norikazu N, Yoshikawa D, Watanabe LA, et al (2004). Synthesis and histone deacetylase inhibitory activity of cyclic tetrapeptides containing a retrohydroxamate as zinc ligand. Bioorg Med Chem Lett, 14, 2427-31. DOI ScienceOn |
2 | Rosato RR, Almenara JA, Grant S (2003). The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res, 63, 3637-45. |
3 | Singh EK, Ravula S, Pan CM, et al (2008). Synthesis and biological evaluation of histone deacetylase inhibitors that are based on FR235222: A cyclic tetrapeptide scaffold. Bioorg Med Chem Lett, 18, 2549-54. DOI ScienceOn |
4 | Sundstrom C, Nilsson K (1976). Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer, 17, 565-77. DOI |
5 | Vega RB, Matsuda K, Oh J, et al (2004). Histone Deacetylase 4 Controls Chondrocyte Hypertrophy during Skeletogenesis. Cell, 119, 555-66. DOI ScienceOn |
6 | Walton JD (2006). HC-toxin. Phytochemistry, 67, 1406-13. DOI ScienceOn |
7 | Wang Y, Wang SY, Zhang XH, et al (2007). FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70. Biochem Bioph Co, 356, 998-1003. DOI ScienceOn |
8 | Ahn MY, Kang DO, Na YJ, et al (2012). Histone deacetylase inhibitor, apicidin, inhibits human ovarian cancer cell migration via class II histone deacetylase 4 silencing. Cancer Lett, 325, 189-99. DOI ScienceOn |
9 | Andersson LC, Nilsson K, Gahmberg CG (1979). K562--A human erythrolekemic cell line. Int J Cancer, 23, 143-7. DOI |
10 | Aversanaa CD, Leporeb I, Altucci L (2012). HDAC modulation and cell death in the clinic. Exp Cell Res, 318, 1229-44. DOI ScienceOn |
11 | Bhuiyan MP, Kato T, Okauchi T, et al (2006). Chlamydocin analogs bearing carbonyl group as possible ligand toward zinc atom in histone deacetylases. Bioorg Med Chem, 14, 3438-46. DOI ScienceOn |
12 | Byrd JC, Marcucci G, Parthun MR, et al (2005). A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood, 105, 959-67. |
13 | Collins SJ (1987). The HL-60 Promyelocytic Leukemia Cell Line: Proliferation, Differentiation, and Cellular Oncogene Expression. Blood, 70, 1233-44. |
14 | Editorial (2009). HDAC inhibitors in leukemia: Current status and perspectives. Leukemia Res, 33, 207-8. DOI ScienceOn |
15 | Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK (2005). Interactive effects of HDAC in hibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia, 7, 646-57. DOI |
16 | Furumai R, Matsuyama A, Kobashi N, et al (2002). FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 62, 4916-21. |
17 | Grant C, Rahman F, Piekarz R, et al (2010). Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticanc, 10, 997-1008. DOI ScienceOn |
18 | Gu WX, Cueto M, Jensen PR, et al (2007). Microsporins A and B: new histone deacetylase inhibitors from the marinederived fungus Microsporum cf. gypseum and the solidphase synthesis of microsporin A. Tetrahedron, 63, 6535-41. DOI ScienceOn |
19 | Goodsell DS, Morris GM, Olson AJ (1996). Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit, 9, 1-5. DOI ScienceOn |
20 | Gottlicher M, Minucci S, Zhu P, et al (2001). Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Eur Mol Biol Org, 20, 6969-78. DOI ScienceOn |
21 | Grant,S, Chris E; Peter K (2007). Vorinostat. Nat Rev Drug Discov, 6, 21. DOI ScienceOn |
22 | Huang WJ, Chen CC, Chao SW, et al (2011). Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors. Eur J Med Chem, 46, 4042-9. DOI ScienceOn |
23 | Humeniuk R, Mishra PJ, Bertino JR, Banerjee D (2009). Molecular targets for epigenetic therapy of cancer. Curr Pharm Biotechnol, 10, 161-5. DOI ScienceOn |
24 | Im JY, Park H, Kang KW, et al (2008). Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and -negative human breast cancer cells. Chem Biol Interact, 172, 235-44. DOI ScienceOn |
25 | Islam NM, Kato T, Nishino N, et al (2010). Bicyclic peptides as potent inhibitors of histone deacetylases:Optimization of alkyl loop length. Bioorg Med Chem Lett, 20, 997-9. DOI ScienceOn |
26 | Morris GM, Goodsell DS, Halliday RS, et al (1998). Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem, 19, 1639-62. DOI ScienceOn |
27 | Josea B, Onikib Y, Kato T, et al (2004). Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones. Bioorg Med Chen Lett, 14, 5343-6. DOI ScienceOn |
28 | Josea B, Okamura S, Kato T, et al (2004). Toward an HDAC6 inhibitor: synthesis and conformational analysis of cyclic hexapeptide hydroxamic acid designed from -tubulin sequence. Bioorg Med Chem, 12, 1351-6. DOI ScienceOn |
29 | Matsuoka H, Fujimura T, Hayashi M, et al (2007). Disruption of HDAC4/N-CoR complex by histone deacetylase inhibitors leads to inhibition of IL-2 gene expression. Biochem Pharmacol, 74, 465-76. DOI ScienceOn |
30 | Morris GM, Huey R, Lindstrom W, et al (2009). AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility. J Comput Chem, 30, 2785-91. DOI ScienceOn |
31 | Morris GM, Huey R, Olson AJ (2008). Using AutoDock for ligand-receptor docking. Curr Prots in Bioinform, 24, 1-40. |
32 | Norikazu N, Jose B, Shinta R, et al (2004). Chlamydocin– hydroxamic acid analogues as histone deacetylase inhibitors. Bioorg Med Chem, 12, 5777-84. DOI ScienceOn |
33 | Nishino N, Shivashimpi GM, Soni PB, et al (2008). Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides. Bioorg Med Chem, 16, 437-45. DOI ScienceOn |